The Role of Isotretinoin Therapy for Cushing’s Disease: Results of a Prospective Study
Table 1
Characteristics of patients.
Patients
Age (years)
Gender
BaselineUFC (g/24 h)
Last UFC (g/24 h)
Baseline ACTH (pg/mL)
Last ACTH (pg/mL)
Baseline MSC (ng/dL)
Last MSC (ng/dL)
Isotretinoin dose (mg/d)
Treatment duration (months)
MRI findings
30
Male
168
89.5
65.6
45.4
174
96.6
60
12
SRT
34
Male
142.6
85.5
41.7
41.2
158.6
92.5
60
12
ES
38
Male
220
83.3
42.2
44.3
174.6
90.4
60
12
SRT
4
52
Female
219
87.7
66.6
44.1
166.7
97.4
80
12
NVT
5
53
Female
223.4
127
79.4
49.7
212.4
133.8
80
12
SRT
6
45
Male
261.3
160.7
44.6
49.9
230
170
80
12
ES
7
44
Male
233.7
112
45.4
48.8
166.4
139
80
6
ES
8
39
Male
293.5
251.5
69.3
69.5
188
121
80
6
NVT
9
41
Male
312.8
171.5
74.4
77.7
272
199.4
80
6
SRT
10
40
Male
280
239.9
77.2
71.4
250
200
80
6
SRT
11
48
Female
215.5
165.2
45.8
43.4
317.6
214.3
80
6
NVT
12
50
Female
250.3
185
42.8
41.7
255
130.7
80
6
NVT
13
51
Female
236
142.3
44.4
43.2
210
154
80
6
NVT
14
53
Female
250.22
195.6
89.4
77.8
238.4
212.6
80
6
SRT
15
53
Female
187.4
144
63
54.4
210.4
178.4
80
6
SRT
16
30
Male
206.4
154
71.1
62.2
209
172
80
6
SRT
Responsive patients, 1 to 4; nonresponsive patients, 5 to 16. UFC, urinary free cortisol; MSC, midnight salivary cortisol; SRT, small residual tumor; ES, empty sella; and NVT, no visible tumor. Normal ranges: UFC, 10–90 g/24 h; ACTH, <46 pg/mL; and MSC, up to 100 ng/dL.
